Clinical trial of WT1 peptide therapy after WT1 and/or tumor lysates-pulsed dendritic cell vaccination therapy for patients with malignant glioma

Clinical trial of WT1 peptide therapy after WT1 and/or tumor lysates-pulsed dendritic cell vaccination therapy for patients with malignant glioma - Clinical trial of WT1 peptide therapy after WT1 and/or tumor lysates-pulsed dendritic cell vaccination therapy for patients with malignant glioma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008397

Enrollment

Registered

2012-08-01

Start date

2012-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant glioma

Interventions

One mg of WT1 peptide is injected into the axillary areas with 1Ke of OK-432 at intervals of 2 weeks for 12 consecutive weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologially Grade 3 or Grade 4 glioma was confirmed 2) The patient had already received standard therapy including conventional radiotherapy and chemotherapy, and WT1 and/or tumor lysates-pulsed dendrite cell vaccination. 3) Age: more than 20 years 4) Karnofsky Performance Status (KPS): more than 60% 5) Estimated survival of more than 3 months 6) No severe organ dysfunction 7) The written informed consent of the patient

Exclusion criteria

Exclusion criteria: 1) The patient had received the WT1 peptide therapy previously.

Design outcomes

Primary

Measure	Time frame
The safety and the efficacy of clinical findings and tumor size on MR images are analyzed 12 weeks after the initial WT1 peptide vaccination.	—

Countries

Japan

Contacts

Public ContactShigetaka Shimodaira

Shinshu University Hospital Cell Processing Center

0263-37-3240

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026